MWI Animal Health and FluoretiQ Form Strategic Alliance to Launch ‘Veri-5 Vet’ Rapid UTITest

LONDON, UNITED KINGDOM — In a major move to advance antimicrobial stewardship across UK veterinary clinics, MWI Animal Health UK has entered into an exclusive strategic distribution partnership with biotechnology innovator FluoretiQ Limited.

The alliance will grant MWI’s extensive network of independent veterinary practices and purchasing group members immediate commercial access to Veri-5 Vet—FluoretiQ’s proprietary, next-generation point-of-care (POC) diagnostic platform. The system is engineered to accurately detect and identify bacterial strains in suspected Urinary Tract Infections (UTIs) within minutes, completely bypassing traditional, multi-day laboratory culture bottlenecks.

Clinical Technology: Eliminating the 48-Hour Culturing Wait

Urinary tract infections represent one of the most frequent drivers of empirical antibiotic prescriptions in small animal veterinary medicine. Historically, practitioners facing a symptomatic feline or canine patient have had to choose between two challenging clinical pathways:

1. Sending urine samples to external reference laboratories for standard Culture and Sensitivity (C&S) testing, which incurs an operational lag of 48 to 72 hours.

2. Prescribing broad-spectrum, empirical frontline antibiotics immediately to alleviate patient discomfort, a practice that contributes directly to the rise of multi-drug resistant (MDR) pathogens.

15-Minute Fluorimetric Technology

The Veri-5 Vet platform utilizes advanced fluorimetric probe technology to identify bacterial pathogens directly in the clinic’s treatment room.

The benchtop analyzer works by targeting specific carbohydrate structures on the surfaces of bacterial cell walls. Within 15 minutes, the assay determines not only the presence of a bacterial infection but also identifies specific pathogen families (such as Escherichia coli, Proteus spp., and Klebsiella spp.). This rapid turnaround allows veterinarians to choose and dispense targeted, narrow-spectrum antibiotics during the initial consultation.

Strategic Implementation & Buying Group Financial Impacts

For MWI Animal Health—a dominant wholesale distributor and veterinary support provider in the UK—the inclusion of FluoretiQ’s platform delivers a high-margin diagnostic asset to its purchasing members.

• • Volume-Discounted Scale: By leveraging MWI’s extensive buying group power, independent clinics can procure the Veri-5 Vet analyzer and disposable assay cartridges at volume-discounted rates, significantly lowering the initial barrier to entry for smaller practices

  • Retaining Diagnostic Revenue: Instead of leaking diagnostic margins to external corporate reference laboratories, the Veri-5 Vet system enables practices to monetize diagnostic workflows entirely in-house. This shift establishes a consistent, high-margin revenue track that helps offset rising clinical overhead costs

  • Streamlining Laboratory Workflows: Minimizing the administrative time spent packaging, logging, and shipping raw urine samples frees up veterinary nursing teams to focus on direct patient care and advanced in-clinic procedures

With regulatory bodies actively monitoring the overuse of critical human-grade antibiotics (such as fluoroquinolones and third-generation cephalosporins) in companion animals, having an auditable, data-proven diagnostic result before opening an antibiotic vial shields veterinary practices from compliance audits. It also enhances client trust by demonstrating a commitment to evidence-based medicine.

Management Perspectives

“Speed and diagnostic accuracy are critical when managing acute infections in companion animals,” stated a spokesperson for MWI Animal Health UK. “By bringing FluoretiQ’s Veri-5 Vet platform into our buying group ecosystem, we are equipping our members with a world-class diagnostic tool that protects profitability, optimizes clinic workflows, and supports the global fight against antimicrobial resistance.”

FluoretiQ Management added: “This partnership with MWI represents a vital milestone in our mission to decentralize precision diagnostics. Moving our platform into hundreds of independent practices across the UK ensures that veterinarians can make confident, data-driven treatment choices in real time, elevating the standard of care for pets and owners alike.”